CommercialPrior AuthMedium impact
Travoprost Intracameral Implant (iDose TR®)
BCBS Tennessee·TN · Ophthalmology·Medical Policy
Effective date
Jul 31, 2026
We identified it
Jun 17, 2026
Summary
BlueCross BlueShield of Tennessee is implementing a new medical policy for Travoprost Intracameral Implant (iDose TR®) for treating open-angle glaucoma and ocular hypertension. The policy requires prior authorization with specific documentation including corneal endothelial cell density measurements and strict exclusion criteria.
Action Required
Before July 31, 2026: Billing team must implement prior authorization requirements for iDose TR® implant procedures. Update billing system to flag these cases and create workflow to collect required documentation: baseline corneal endothelial cell density measurements, diagnosis confirmation for open-angle glaucoma or ocular hypertension, and verification patient meets exclusion criteria. Train ophthalmology staff on new documentation requirements. Claims will require prior auth or face denial.